Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT07670715 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT07670715
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed through a tissue biopsy with a type of lung cancer called non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has not spread beyond the chest area (stage III locally advanced).
  • People who have already received at least 2 rounds of a standard combination of chemotherapy and immunotherapy before this trial, where scans have shown the tumour did not respond well enough to that treatment.
  • People who are 18 years of age or older.
  • People whose general health and ability to carry out daily activities meets a certain standard, as measured by a scoring system doctors use (a score of 0 or 1 on the ECOG scale, meaning fully active or able to carry out light activity).
  • People whose blood counts and kidney, liver, and bone marrow function are at a level considered adequate to safely complete radiation therapy and ongoing cancer treatment.
  • People who are willing to sign a consent form and are able to follow the steps required throughout the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously had radiation therapy to the chest area.
  • People who have autoimmune conditions (where the immune system attacks the body) that are currently active and not under control, or who have had serious ongoing side effects from immune-related treatments.
  • People who have cancer that has spread to the brain and is causing symptoms that have not yet been treated.
  • People who have serious, permanent problems with the heart, lungs, liver, or kidneys that would make it unsafe to receive both radiation therapy and immunotherapy together.
  • People who are currently pregnant or breastfeeding.
  • People who have had another type of cancer within the past 5 years, except for certain types that are considered fully cured (specifically, a type of skin cancer called basal cell carcinoma, or early-stage cervical cancer that had not spread).
  • People for whom radiation therapy of a specific type used in this trial, or immune checkpoint inhibitor medications, would be medically unsafe or not recommended (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026

Contact this trial

Phone: +8615602036608

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate; Pathological complete response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov